PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026Case Reports in Infectious Diseases0 citationsOpen Access

Successful Treatment of Lactobacillus rhamnosus Endocarditis With Intravenous Daptomycin: A Case Report and Literature Review

View Full Paper
MRMehboob A. RehanJBJ. Todd BagwellSWS. Blake Wachter

Key Points

  • Daptomycin effectively treats lactobacillus rhamnosus endocarditis, demonstrating promising clinical outcomes.
  • A 6-week course of intravenous daptomycin allowed successful management of a complex case, ensuring patient recovery.
  • Challenges in treatment arise mainly from antibiotic resistance, particularly with vancomycin and penicillin allergies.
  • The findings highlight a potential alternative for treating infections caused by lactobacillus species.

Abstract

Lactobacilli are Gram-positive, facultatively aerobic, rod-shaped bacteria that are a normal part of the human microbiota and rarely cause infections in immunocompetent hosts. Lactobacillus casei and Lactobacillus rhamnosus are the most common human pathogens within this genus and are also frequently used in probiotics. Both species are inherently resistant to vancomycin, and penicillin-sometimes in combination with aminoglycosides-remains the primary treatment for infections caused by these organisms. Management becomes particularly challenging in patients with severe penicillin allergies, such as anaphylaxis. Although daptomycin has demonstrated in vitro activity against these pathogens, clinical data on its use are limited. Here, we present a case of Lactobacillus rhamnosus endocarditis successfully treated with 6 weeks of intravenous daptomycin.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rehan et al. (2026) studied this question.

synapsesocial.com/papers/69a75b2bc6e9836116a22011https://doi.org/10.1155/crdi/9295802
Ask AI
Helpful
Bookmark
Share
View Full Paper